These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27678370)

  • 1. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.
    Kourlaba G; Gourzoulidis G; Andrikopoulos G; Tsioufis K; Beletsi A; Maniadakis N
    BMC Health Serv Res; 2016 Sep; 16(1):520. PubMed ID: 27678370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
    Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
    BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
    Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
    Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
    Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
    BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
    Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
    Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
    Nguyen E; Coleman CI; Kohn CG; Weeda ER
    Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain.
    Kumar K; Rizvi S
    Pain Med; 2013 Nov; 14(11):1631-49. PubMed ID: 23710759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
    Coleman CI; Freemantle N; Kohn CG
    BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN TREATMENT OF PATIENTS WITH HEART FAILURE IN IRAN.
    Taheri S; Heidari E; Aivazi MA; Shams-Beyranvand M; Varmaghani M
    Int J Technol Assess Health Care; 2018; 34(6):576-583. PubMed ID: 30560749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
    Teti VP; Akdagli S; Most SP
    JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA
    Watada H; Sakamaki H; Yabe D; Yamamoto F; Murata T; Hanada K; Hirase T; Okamura T
    Diabetes Ther; 2020 Aug; 11(8):1721-1734. PubMed ID: 32557283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.